Nebivolol: No Limb Pain?
Beta-blockers are routinely prescribed often as first-line therapy for various cardiovascular diseases such as coronary heart disease and heart failure. Much of their prescribing relates to the benefits of the newer generation of beta-blockers and greater cardio-selectivity. One of the challenges all clinicians face is to manage the choice of numerous beta-blockers and in particular translating the evidence base to real-world practice.
This webinar will provide an overview of the evidence of beta-blockers, and present some key differences between the agents. The webinar will also discuss, through the use of cases, the management of patients who are often excluded from clinical trials, in particular the elderly.
This live webinar is EBAC accredited. 1 CME credit will be granted upon confirmation of successful attendance.
This is an independent activity run by the International Society of Cardiovascular Pharmacotherapy (ISCP) and co-produced in collaboration with Radcliffe Cardiology.
Sang Hong Baek
Bernard Man Yung Cheung
This webinar is supported by
Nebivolol: No Limb Pain?
12:00-13:00 GMT/ 13:00-14:00 CET/ 20:00-21:00 HKT & ULAT
- Welcome words
- Nebivolol: No Limb Pain? Lecture by Dr Sang Hong Baek
- Case 1 &2 Presentations & Panel Discussion
- Audience Q & A
Key Learning Objectives
- To describe the evidence base of beta-blockers in cardiovascular disease including heart failure with particular reference to nebivolol
- List out the key differences of beta-blockers with regard to patient population in clinical trials and characteristics of the various agents
- To analyse special and regional issues that impact the use of this drug
- To apply evidence-based recommendations to two real world cases
- Cardiovascular team members - doctors, nurses, pharmacists
- Family physicians
- Healthcare students and trainees
- Cardiovascular pharmacotherapy researchers
Sang Hong Baek
Professor Sang Hong Baek, MD, PhD, FACC, FESC, is an Emeritus Professor at The Catholic University of Korea and the President of the International Society of Cardiovascular Pharmacotherapy (2023).
He has held several prestigious positions, including former President of the Korean Society of Lipid and Atherosclerosis, Korean Society of Cardio Cerebrovascular Disease Prevention, and Korean Society of Cardiovascular Pharmacotherapy.
Professor Baek also serves as an editorial board member for several cardiovascular journals, including the European Heart Journal (EHJ), where he is an Associate Editor for EHJ-Cardiovascular Pharmacotherapy, as well as the International Journal of Cardiology and Current Hypertension Reports.
Bernard Man Yung Cheung
Bernard Man Yung Cheung is a Professor in Cardiovascular Therapeutics and heads the Division of Clinical Pharmacology and Therapeutics in the Department of Medicine at the University of Hong Kong's School of Clinical Medicine.
His research interests primarily focus on cardiovascular diseases and risk factors, including hypertension and metabolic syndrome.
Professor Yeh also serves as the Chief Editor for the Postgraduate Medical Journal (PMJ) and previously held the position of Chief Editor for Open Diabetes and the World Journal of Hypertension.
Specialist in: cardiology, internal medicine, arterial hypertension, clinical pharmacology (4 certified specializations).
Education: Medical University of Warsaw (MUW), MD, PhD.
Scientific and clinical internships: Medical Faculty, Utrecht University, Netherlands, Medical Faculty, Amsterdam University, Netherlands, Internal Medicine Department, Gaffree e Guinle University, Rio de Janeiro, Brazil, Department of Pharmacology, University of Geneva, Switzerland; Erasmus Programme for University Teachers' Exchange, Milan, Italy; University of Nis, Serbia: visiting professor.
Affiliations: Maria Sklodowska-Curie Medical Academy in Warsaw – Professor and Rector Magnificus since 2021; former: MUW Vice Dean for Science, Medical Faculty 2012-16; Deputy Rector Magnificus, MUW 2016-19; Dean for Science/Medical Sciences Council Chairman in MUW 2019-20;
Medical association memberships: Polish Cardiac Society (PCS): Chairman of Polish Top Junior Cardiologists ,,Club 30” 2007-09; Co-founder and first Chairman of PCS Cardiovascular Pharmacotherapy Working Group 2010-13; Polish Society of Hypertension: President 2018-20; Past-President 2020-22; International Society of Cardiovascular Pharmacotherapy – Governor for Poland 2016 -; European Society of Cardiology - member of the Working Group on Acute Cardiac Care and the Working Group on Cardiovascular Pharmacotherapy; Fellow of European Society of Cardiology 2009;
Research interests: dyslipidaemias, acute coronary syndromes, heart failure, stable angina, cardiovascular pharmacotherapy, renin-angiotensin system, platelets, coagulation, post-COVID, LONG COVID syndromes.
Papers: over 550 indexed in PubMed MEDLINE; according to Google Scholar database (April, 2022): 8016 citations, Hirsch index = 41; i-10 index = 194.
Textbooks: Author and co-author about 100 chapters in monographs and textbooks; co-author and co-editor in Polish e.g.: [Renin-Angiotensin System Drugs], Opolski G, Filipiak KJ, eds., 2000; [Statins - The Basic Clinical Pharmacology], Filipiak KJ, Opolski G, eds., 2001; [Acute Coronary Syndromes], Opolski G, Filipiak KJ, Polonski L, eds., 2002; [Hypertension in oncology], Filipiak KJ, Szymanski FM, Szmit S, eds., 2018. [Coronavirus SARS-CoV-2 textbook], Dzieciatkowski T, Filipiak KJ, eds., 2021.
Former Editor-in-chief (2012-2017): Kardiologia Polska [Polish Heart Journal] – the official journal of Polish Cardiac Society, Executive Editor Cardiology Journal (since 2018-); Editorial Board member of Journal of Cardivascular Development and Disease (IF=3,948).
Tutor experience: 22 PhD, including 12 PhD with special distinction; 12 specialists in cardiology, 7 specialists in internal medicine; reviewer of 56 PhD theses.
Clinical trials experience: ALIVE, ONTARGET/TRANSCEND, IMRPOVE-IT, SIGNIFY, Q-SYMBIO.
Dr Ganchimeg Ulziisaikhan is a Cardiologist at the National Cardiovascular Center of the Third State Central Hospital in Mongolia and an active member of the Mongolian Society of Cardiologists.
She holds a Bachelor's and Master's degree in Internal Medicine from Peking University Health Science Center (2009-2012) and received heart failure management training at The National Heart Center of Singapore in 2016.
Dr Ulziisaikhan leads the pilot "Heart Failure Program" at the National Cardiovascular Center, which aims to improve and supervise heart failure management at a national level. She was also part of the task force that developed the first guideline for Heart Failure diagnosis and management.
Mr Sotiris Antoniou is Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust. Combined with his role as Lead Cardiovascular Pharmacist for UCL Partners supports medicines optimisation across the health economy to optimise patient outcomes and address unmet local needs. He is an independent prescriber and is currently chair of the cardiac committee for United Kingdom Clinical Pharmacy Association (UKCPA). He is chair of the DRM-foundation that supports the international Pharmacist Anticoagulation Taskforce (iPACT). A group aimed to improve pharmaceutical care around anticoagulants, by providing background materials and stimulating pharmacists to provide appropriate care to their patients.
He has published extensively in the medical press and has a particular interest in improving anticoagulation for stroke prevention in atrial fibrillation. Sotiris has been successful in obtaining a Lord Darzi funded fellow to ‘co-design and test a new referral pathway for people with atrial fibrillation with community pharmacists’ with the aim to support individuals' understanding of their condition and their therapy with the ultimate aim of optimising adherence.
He is actively involved in the training and development of clinical pharmacists including developing a curriculum and assessment tool for advanced and consultant level specialist cardiac pharmacists working with the UKCPA and Royal Pharmaceutical Society.
Mr Antoniou has served on many NICE development groups including Unstable Angina/NSTEMI guideline, stable angina and STEMI guidelines and is a current NICE TA member of the highly specialist technology appraisal group. He is also a member of the London Strategic Clinical Network Cardiovascular Leadership Group and NHS England Medicines Optimisation Intelligence Group meeting. Sotiris is also an honorary senior research associate at UCL School of Pharmacy.